China’s first patent for a COVID-19 vaccine has been granted by the National Intellectual Property Administration.
The patent was jointly applied for by a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company, said a report in People’s Daily.
Chen Wei led the team, who is working as a researcher at the Institute of Military Medicine under the academy. The team developed the recombinant COVID-19 vaccine, with the modified defective adenovirus as the vector.
In March, the vaccine became the first in China to be approved to enter clinical trials.
As stated by the patent abstract, the vaccine shows good immunogenicity in both mouse and guinea pig models and can induce strong cellular and humoral immune response in a short period of time. It can be produced quickly on a large scale to cope with a COVID-19 outbreak.
Phase-1 and phase-2 clinical trials of the vaccine have been finished, its safety and immunogenicity have been verified in the trials, said the report.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.